Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 2 (2019)

Effectiveness of metabolic therapy in patients with acute coronary syndrome (ACS) - myocardial infarction (MI) with disfunctional liver conditions

Author(s):
Shved MI, Tsuglevich LV, Heryak SM and Prokopovich OA
Abstract:
The purpose of this work was to improve the existing therapeutic programs of ACS (myocardial infarction) by differentiated approach to therapy depends of the presence or absence of violations of the liver functional state. There are a violation of central and peripheral hemodynamics, endothelial function of the vessels in patients with myocardial infarction, which leads to a violation of protein synthesis, detoxification, energy-supplying function of the liver, lipid metabolism. At the same time excessive activation of peroxide processes of lipids, suppresses the activity of enzymes of the antioxidant system enhances pathological processes in the heart and liver. Violation of the functional state of the liver in patients with myocardial infarction significantly impairs the clinical course of the basic pathological process, further exacerbates the violation of systolic and diastolic function of the heart and contributes to the more frequent development of complications of ACS (MI). Inclusion in the complex program of patients treatment with acute coronar syndrome (MI) L-arginine and L-carnitine contributes to the restoration of endothelial function of blood vessels, antioxidant protection of the body and increases energy supply of myocarditis, which is accompanied with the improvement of contractile myocardium function and reduction of clinical and laboratory manifestations of cytolytic and cholestatic syndromes in these patients.
Pages: 200-204  |  665 Views  72 Downloads


The Pharma Innovation Journal
How to cite this article:
Shved MI, Tsuglevich LV, Heryak SM, Prokopovich OA. Effectiveness of metabolic therapy in patients with acute coronary syndrome (ACS) - myocardial infarction (MI) with disfunctional liver conditions. Pharma Innovation 2019;8(2):200-204.

Call for book chapter